Basic Information
| LncRNA/CircRNA Name | PCAT29 |
| Synonyms | PCAT29 |
| Region | GRCh38_15:69592200-69695750 |
| Ensemble | ENSG00000259641 |
| Refseq | NR_126437 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | Microarray, qPCR etc. |
| Sample | cell lines (Glutamax(Invitrogen), LNCaP, DU145 etc.) |
| Expression Pattern | down-regulated |
| Function Description | PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. PCAT29 as an androgen-regulated tumor suppressor in prostate cancer. |
| Pubmed ID | 25030374 |
| Year | 2014 |
| Title | The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. |
External Links
| Links for PCAT29 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |